What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.”In the company’s words, NCT06466135 on ClinicalTrials.gov
- Tested for
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
- Main trialPhase 2
- “This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change disease \[TR MCD\], primary immunoglobulin A nephropathy \[IgAN\], and primary membranous nephropathy \[PMN\]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or…”In the company’s words, NCT06466135 on ClinicalTrials.gov
Other drugs for Diabetic Nephropathies
- R3R01River 3 Renal Corp. · Phase 2
- IsuzinaxibAptabio Therapeutics, Inc. · Phase 2
- Umbilical Cord Mesenchymal Stem CellsPT. Prodia Stem Cell Indonesia · Phase 1/2
- ALN-ANG3Regeneron · Phase 2
- EvinacumabRegeneron · Phase 2
- AtrasentanNovartis · Phase 2
Coming up1
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Mar 2027 | Study of WAL0921 in Patients With Glomerular Kidney Diseases | |
| Phase 1Completed | 9 Jan 2024 | Single Ascending Dose Study of WAL0921 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026